Last updated on June 2019

Oral Anticoagulation in Haemodialysis Patients


Brief description of study

Guidelines recommend oral anticoagulation with vitamin K antagonists for atrial fibrillation whenever the CHADS2VASC score is superior or equal to 2. As there are no specific guidelines for the hemodialysis patients with atrial fibrillation, the general guidelines apply. However, several retrospective studies suggest that these patients do not benefit from the oral anticoagulation regarding the risk of stroke and may even experience more bleedings and deaths.

The aim of this prospective study is to prospectively compare the hemorrhagic and thrombotic risks of oral anticoagulation in comparison with no anticoagulation in hemodialysis patients with atrial fibrillation.

Clinical Study Identifier: NCT02886962

Find a site near you

Start Over

Service de N phrologie

Cherbourg-Octeville, France
  Connect »

Aurad Aquitaine

Gradignan, France
  Connect »

ECHO CA Laennec

Saint-Herblain, France
  Connect »

N phroCare Tassin-Charcot

Sainte-Foy-lès-Lyon, France
  Connect »

AURAL st Anne

Strasbourg, France
  Connect »

N phroCare Tassin-Charcot

Sainte-Foy-lès-Lyon, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.